HYHisano Yajima

Hisano Yajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hisano Yajima has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Takao Hashiguchi

    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan

    4 shared publications
  • Katsumi Maenaka

    Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

    3 shared publications
  • Kei Sato

    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo

    3 shared publications
  • Shunsuke Kita

    Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

    3 shared publications
  • Yuki Anraku

    Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

    3 shared publications
  • Arnon Plianchaisuk

    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    2 shared publications

Latest Publications

  • Open Access

    Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants

    by Hisano Yajima, Tomo Nomai, Kaho Okumura, Katsumi Maenaka, Keita Matsuno, Jumpei Ito, Takao Hashiguchi, Kei Sato

    Due to the incessant emergence of various SARS-CoV-2 variants with enhanced fitness in the human population, controlling the COVID-19 pandemic has been challenging. Understanding how the virus enhances its fitness during a pandemic could offer valuable insights for more effective control of viral epidemics. In this manuscript, we review the evolution of SARS-CoV-2 from early 2022 to the end of 2023—from Omicron BA.2 to XBB descendants. Focusing on viral evolution during this period, we provide concrete examples that SARS-CoV-2 has increased its fitness by enhancing several functions of the spike (S) protein, including its binding affinity to the ACE2 receptor and its ability to evade humoral immunity. Furthermore, we explore how specific mutations modify these functions of the S protein through structural alterations. This review provides evolutionary, molecular, and structural insights into how SARS-CoV-2 has increased its fitness and repeatedly caused epidemic surges during the pandemic.


  • Open Access

    Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1

    by Hisano Yajima, Yuki Anraku, Yu Kaku, Kanako Terakado Kimura, Arnon Plianchaisuk, Kaho Okumura, Yoshiko Nakada-Nakura, Yusuke Atarashi, Takuya Hemmi, Daisuke Kuroda, et al.

    Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.


  • Open Access

    A triggering structure of SARS-CoV-2 BA.2.86 spike upon ACE2 binding for receptor-binding domain up

    by Takao Hashiguchi, Hisano Yajima, Yuki Anraku, Yu Kaku, Kanako Kimura, Arnon Plianchaisuk, Kaho Okumura, Yoshiko Nakada-Nakura, Shunsuke Kita, Jiei Sasaki, et al.

    Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, is believed to bind to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the “up” conformation. However, whether ACE2 exclusively binds to the “up” RBD or also interacts with the “down” RBD to facilitate the conformational shift to RBD-up remains unclear. Here, we present the structures of the BA.2.86 spike alone and bound to ACE2. The N354-linked glycan contributes to the neutralizing antibody evasion in BA.2.86. Notably, we successfully observed the ACE2-bound “down” RBD, indicating a trigger structure before the RBD-up conformation. The wider and mobile angle of RBDs in the “up” state provides space for ACE2 to interact with the “down” RBD, facilitating the transition to the RBD-up state. These structural insights into the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.

  • Top Cited Papers
    Open Access

    Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

    by Tomokazu Tamura, Takashi Irie, Sayaka Deguchi, Hisano Yajima, Masumi Tsuda, Hesham Nasser, Keita Mizuma, Arnon Plianchaisuk, Saori Suzuki, Keiya Uriu, et al.

    Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.